Metformin
Also known as: Glucophage, Glucophage XR
Biguanide | AMPK Activator & Longevity Research
Overview
Metformin is a biguanide compound and the most widely prescribed oral medication for type 2 diabetes mellitus worldwide, with over 150 million prescriptions annually. Originally derived from the French lilac (Galega officinalis), metformin was introduced in clinical practice in the 1950s in Europe and received FDA approval in the United States in 1995. Beyond its well-established role in glucose regulation, metformin has attracted significant attention in longevity and aging research. The Targeting Aging with Metformin (TAME) trial, a landmark multi-center study, is investigating whether metformin can delay the onset of age-related diseases in non-diabetic older adults. Observational data have suggested that diabetic patients taking metformin may have lower all-cause mortality than age-matched non-diabetic controls, prompting serious scientific interest in its potential geroprotective properties.
Key benefits
- Improved insulin sensitivity and glucose regulation
- Activation of AMPK, the master metabolic energy sensor
- Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
- Reduced hepatic glucose output (gluconeogenesis suppression)
- Modest weight loss or weight neutrality compared to other diabetes medications
- Anti-inflammatory effects through NF-kB pathway suppression
- Potential anti-cancer properties via mTOR inhibition and AMPK activation
- Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Mechanism of action
Metformin exerts its primary effects through activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. AMPK activation triggers a cascade of downstream metabolic improvements: enhanced glucose uptake in skeletal muscle, suppression of hepatic gluconeogenesis, improved mitochondrial function, and increased fatty acid oxidation. Metformin also inhibits Complex I of the mitochondrial electron transport chain, which contributes to its AMPK-activating effects by increasing the AMP-to-ATP ratio. Beyond glucose metabolism, metformin modulates several pathways implicated in aging, including inhibition of mTOR signaling (a key regulator of cellular growth and senescence), reduction of oxidative stress and reactive oxygen species, attenuation of chronic low-grade inflammation via NF-kB pathway suppression, and activation of autophagy. These pleiotropic mechanisms underpin both its antidiabetic efficacy and its potential as an anti-aging compound.
Molecular data
- Type
- Biguanide (C4H11N5)
- Half-life
- ~5 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Metabolic Health
Type 2 Diabetes Mellitus
Most effectiveFirst-line pharmacotherapy for type 2 diabetes per ADA/EASD guidelines. Reduces HbA1c by 1.0-1.5% as monotherapy. Proven cardiovascular mortality reduction in the UKPDS trial. Can be used alone or in combination with other antidiabetic agents.
Prediabetes / Insulin Resistance
EffectiveDelays or prevents progression from prediabetes to type 2 diabetes. The Diabetes Prevention Program (DPP) showed a 31% reduction in diabetes incidence with metformin compared to placebo over 2.8 years. Particularly effective in younger, more obese individuals.
Metabolic Syndrome
EffectiveImproves multiple components of metabolic syndrome including fasting glucose, insulin resistance, and visceral adiposity. Often used off-label in non-diabetic individuals with metabolic syndrome who have failed lifestyle interventions.
Polycystic Ovary Syndrome (PCOS)
ModerateImproves insulin resistance, reduces androgen levels, and may restore ovulatory function in women with PCOS. Used as adjunctive therapy alongside lifestyle modifications. Effectiveness varies and is most pronounced in women with significant insulin resistance.
Longevity / Anti-Aging
Geroprotection / Healthspan Extension
Under researchObservational studies suggest diabetic patients on metformin may have lower all-cause mortality than non-diabetic controls. The TAME trial is the first FDA-approved clinical trial to specifically target aging as an indication. Proposed mechanisms include AMPK activation, mTOR inhibition, reduced inflammation, and enhanced autophagy.
Cancer Risk Reduction
Under researchMultiple observational studies and meta-analyses suggest 20-40% reduced incidence of several cancers (colorectal, breast, prostate, pancreatic) in metformin users versus other antidiabetic therapies. Proposed mechanisms include AMPK-mediated mTOR inhibition and reduced circulating insulin/IGF-1 levels. Prospective clinical trials are ongoing.
Cardiovascular Protection
EffectiveThe UKPDS demonstrated a 39% reduction in myocardial infarction risk in overweight diabetic patients treated with metformin. Mechanisms include improved endothelial function, reduced oxidative stress, and anti-inflammatory effects independent of glucose lowering.
Body Composition
Weight Management
ModerateMetformin is weight-neutral to mildly weight-reducing, unlike many other diabetes medications. Typical weight loss is 1-3 kg over 6-12 months. May reduce visceral fat preferentially. Often prescribed off-label for weight management in non-diabetic individuals with insulin resistance.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Oral
Metformin is administered exclusively by the oral route. It is available in immediate-release (IR) tablets taken 2-3 times daily with meals, and extended-release (XR/ER) formulations taken once daily, typically with the evening meal. The extended-release formulation significantly reduces gastrointestinal side effects and improves adherence. Metformin is not metabolized by the liver and is excreted unchanged by the kidneys, making renal function an important consideration for dosing.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Type 2 Diabetes - Standard Titration Gradual titration over 4-6 weeks minimizes GI side effects. Maximum recommended dose is 2550 mg/day (IR) or 2000 mg/day (XR). Take with food to reduce nausea. | 500 mg, titrate to 1500-2000 mg/day | Start 500 mg once or twice daily, increase by 500 mg weekly | Oral with meals |
| Longevity / Off-Label Geroprotection Lower doses are commonly used in the longevity community. Some clinicians prescribe 500 mg once or twice daily for non-diabetic adults pursuing anti-aging benefits. Extended-release formulation preferred for tolerability. | 500-1000 mg/day | Once or twice daily | Oral with meals |
| Prediabetes / Insulin Resistance Based on DPP trial dosing (850 mg twice daily). Lower doses (500-1000 mg) may be sufficient for individuals with mild insulin resistance. | 500-1500 mg/day | Once or twice daily | Oral with meals |
| PCOS Higher doses often needed for PCOS. Extended-release formulation strongly recommended due to prolonged treatment duration and GI side effect burden. | 1500-2000 mg/day | Divided 2-3 times daily or once daily (XR) | Oral with meals |
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Semaglutide
MonitorFrequently prescribed together for type 2 diabetes as they work through complementary mechanisms. Semaglutide (GLP-1 receptor agonist) and metformin have additive glucose-lowering effects. Monitor for increased GI side effects when initiating the combination, as both agents can cause nausea and gastrointestinal discomfort. Dose titration of both agents should be staggered.
Rapamycin
SynergisticMetformin and rapamycin target complementary longevity pathways. Metformin activates AMPK while rapamycin directly inhibits mTOR. Preclinical studies in mice show the combination extends lifespan more than either compound alone. Some longevity-focused clinicians prescribe both concurrently, though human clinical trial data for the combination is limited.
Testosterone
CompatibleNo significant negative interactions. Metformin may improve metabolic parameters that complement testosterone replacement therapy, particularly in men with metabolic syndrome or insulin resistance. Some evidence suggests metformin may modestly reduce testosterone levels in men, though this effect is clinically insignificant in the context of exogenous testosterone use.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Week 1-2
Gastrointestinal adjustment period is common. Nausea, bloating, and loose stools may occur as the body adapts. Fasting glucose levels begin to decrease. Gradual dose titration helps minimize side effects during this phase.
- Week 2-4
GI side effects typically begin to subside. Fasting blood glucose reductions become more consistent. Appetite may decrease modestly. Energy levels may improve as insulin sensitivity begins to normalize.
- Month 1-3
Measurable reductions in HbA1c (typically 0.5-1.0% by month 3). Improved fasting and postprandial glucose levels. Modest weight stabilization or mild weight loss. Lipid profile improvements may begin to appear.
- Month 3-6
Full glycemic benefits realized with HbA1c reductions of 1.0-1.5%. Improved insulin sensitivity reflected in lower fasting insulin levels. Continued body composition improvements. AMPK-mediated metabolic benefits fully established.
- Month 6+
Long-term metabolic benefits sustained. Cardiovascular risk markers may improve over time. B12 levels should be monitored annually as deficiency can develop with prolonged use. Ongoing renal function monitoring recommended.
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
- Metallic taste in mouth
- Decreased appetite
- Flatulence and abdominal distension
- Loose stools, particularly when initiating therapy or increasing dose
Rare side effects
- Vitamin B12 deficiency (occurs in 5-10% of long-term users, can lead to megaloblastic anemia and peripheral neuropathy if undetected)
- Lactic acidosis (extremely rare but potentially fatal, incidence approximately 3-10 per 100,000 patient-years, almost exclusively in patients with contraindicated renal or hepatic impairment)
- Hypoglycemia (only when combined with sulfonylureas or insulin, not with metformin monotherapy)
Stop signs — stop and seek advice
- Severe persistent nausea, vomiting, or abdominal pain (potential early signs of lactic acidosis)
- Rapid or difficult breathing, unusual drowsiness, or muscle pain (symptoms of lactic acidosis)
- Significant decline in renal function (eGFR below 30 mL/min/1.73m2)
- Severe dehydration or conditions predisposing to acute kidney injury
- Prior to iodinated contrast procedures (hold metformin 48 hours before and after)
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Known hypersensitivity to metformin
- Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
- Severe hepatic impairment
- Excessive alcohol intake (increases risk of lactic acidosis)
Monitoring
- Renal function (eGFR): at baseline, then at least annually; more frequently in patients with declining renal function
- Vitamin B12 levels: at baseline and annually with long-term use (supplement if deficient)
- HbA1c: every 3-6 months until stable, then every 6-12 months
- Complete blood count: annually to monitor for B12 deficiency-related anemia
- Hepatic function: at baseline; periodic monitoring if clinically indicated
- Lactate levels: only if symptoms suggestive of lactic acidosis arise (not routine)
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- Pharmaceutical-grade product from established manufacturer with valid NDC number
- Proper labeling with dosage strength, formulation type (IR or XR), lot number, and expiration date
- Tablets are uniform in size, shape, and color with no chips or discoloration
- Prescribed by licensed physician with appropriate metabolic workup
- Extended-release formulation for improved tolerability and adherence
Warning signs
- Compounded or non-standard formulations without verification of bioequivalence
- Sourced from unverified international pharmacies
- Generic formulation with reported extended-release matrix failures (ghost tablets)
Stop signs — don't use
- Tablets that are crumbling, discolored, or have an unusual odor
- Product past its expiration date
- No labeling or incorrect dosage strength labeling
- Sourced without prescription from unregulated suppliers
Recent research
Newer papers and trial readouts on file for this compound, with source and date.
2023 · American Federation for Aging Research (AFAR)
Targeting Aging with Metformin (TAME) Trial Design and Progress
The TAME trial is the first FDA-approved clinical trial targeting aging as a treatable condition. Enrolling approximately 3,000 non-diabetic adults aged 65-79, the trial will assess whether metformin can delay the composite onset of age-related diseases including cardiovascular disease, cancer, dementia, and mortality.
2022 · European Journal of Cancer Prevention
Metformin and Cancer Risk: A Systematic Review and Meta-Analysis
Updated meta-analysis reinforcing the association between metformin use and reduced cancer incidence across multiple cancer types, with the strongest evidence for colorectal and hepatocellular carcinoma risk reduction.
2023 · Aging Cell
Metformin and Exercise in Aging: Interactions and Implications
Study examining the interaction between metformin and exercise in older adults, noting that metformin may partially blunt some exercise-induced adaptations in mitochondrial respiration and cardiorespiratory fitness, suggesting timing of metformin relative to exercise may be an important consideration.
References
Primary literature and clinical-trial data informing this entry.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
UK Prospective Diabetes Study (UKPDS) Group · The Lancet · 1998
Landmark trial demonstrating that metformin reduced all-cause mortality by 36% and myocardial infarction risk by 39% in overweight patients with type 2 diabetes, establishing metformin as the preferred first-line therapy for type 2 diabetes.
Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin (Diabetes Prevention Program)
Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al. · The New England Journal of Medicine · 2002
The DPP trial showed metformin (850 mg twice daily) reduced the incidence of type 2 diabetes by 31% compared to placebo in high-risk adults with prediabetes. Lifestyle intervention was more effective (58% reduction), but metformin was particularly effective in younger, more obese participants.
Metformin as a Tool to Target Aging
Barzilai, N., Crandall, J.P., Kritchevsky, S.B., Espeland, M.A. · Cell Metabolism · 2016
Review outlining the rationale for the TAME (Targeting Aging with Metformin) trial, summarizing evidence that metformin may delay aging and age-related diseases through AMPK activation, mTOR inhibition, reduced inflammation, and enhanced autophagy.
Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls
Bannister, C.A., Holden, S.E., Jenkins-Jones, S., et al. · Diabetes, Obesity and Metabolism · 2014
Observational study of over 180,000 subjects showing that type 2 diabetic patients initiated on metformin monotherapy had 15% lower all-cause mortality compared to matched non-diabetic controls, sparking widespread interest in metformin as a potential longevity drug.
Metformin: A Review of Its Potential Indications
Romero, R., Erez, O., Huttemann, M., et al. · Drug Design, Development and Therapy · 2017
Comprehensive review of metformin's mechanisms of action and emerging indications beyond diabetes, including cancer prevention, cardiovascular protection, neuroprotection, and anti-aging properties. Highlights AMPK activation as the central mechanism underlying metformin's pleiotropic effects.
Last updated . How this page was sourced is described in the methodology.